Mega startup watch; Interview with Siddhartha Mukherjee; Tracking Wegovy’s long-term effects; Biogen’s ALS flop; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

In a few weeks, I’ll be flying out to San Diego for the annual BIO conference, where Endpoints News will host a parallel event to explore some of the most important issues driving the biopharma industry. Check out the full agenda here.

Mega startup watch

A pair of hefty startups have entered the room to tackle some of the hottest areas in biotech. Blackstone unveiled its $300 million bet on Uniquity Bio, which will test a former Merck monoclonal antibody for atopic dermatitis in asthma and COPD. Meanwhile, Bain, Atlas and RTW are forming a company…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks